Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frederick L Locke

Showing results (111-120 of 234) with videos related to

Pageof 24
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 22, 2023
Survivin Dendritic Cell Vaccine Safely Induces Immune Responses and Is Associated with Durable Disease Control after Autologous Transplant in Patients with MyelomaCiara L Freeman, Reginald Atkins, Indumathy Varadarajan, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 20, 2024
Long-term follow up of the combination of ofatumumab, high-dose methylprednisolone, and lenalidomide for untreated chronic lymphocytic leukemia with biomarker analysisJulio C Chavez, Ariel Grajales, Jose Sandoval-Sus, et al.
American Journal of Hematology|August 16, 2023
The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCLKai Rejeski, Yucai Wang, Omar Albanyan, et al.
Journal of Hematology & Oncology|July 31, 2023
The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myelomaKai Rejeski, Doris K Hansen, Radhika Bansal, et al.
Haematologica|June 13, 2012
A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantationJoseph Pidala, Jongphil Kim, Heather Jim, et al.
Journal for Immunotherapy of Cancer|May 17, 2022
The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCLKai Rejeski, Ariel Perez, Gloria Iacoboni, et al.
Transplantation and Cellular Therapy|January 29, 2023
Paving the Road for Chimeric Antigen Receptor T Cells: American Society for Transplantation and Cellular Therapy 80/20 Task Force Consensus on Challenges and Solutions to Improving Efficiency of Clinical Center Certification and Maintenance of Operations for Commercially Approved Immune Effector Cell TherapiesSarah Nikiforow, Matthew J Frigault, Noelle V Frey, et al.
Transplantation and Cellular Therapy|March 30, 2021
Incidence and Management of Effusions Before and After CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Large B Cell LymphomaAbu-Sayeef Mirza, Ambuj Kumar, Hamza Hashmi, et al.
Transplantation and Cellular Therapy|August 26, 2024
Tocilizumab Prophylaxis Following Axicabtagene Ciloleucel in Relapsed or Refractory Large B-Cell LymphomaFrederick L Locke, Sattva S Neelapu, Nancy L Bartlett, et al.
Journal for Immunotherapy of Cancer|February 9, 2025
Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registryDaniel J Landsburg, Matthew J Frigault, Michael Heim, et al.
Pageof 24

Showing results (111-120 of 234) with videos related to

Sort By:
Pageof 24
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 22, 2023
Survivin Dendritic Cell Vaccine Safely Induces Immune Responses and Is Associated with Durable Disease Control after Autologous Transplant in Patients with MyelomaCiara L Freeman, Reginald Atkins, Indumathy Varadarajan, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 20, 2024
Long-term follow up of the combination of ofatumumab, high-dose methylprednisolone, and lenalidomide for untreated chronic lymphocytic leukemia with biomarker analysisJulio C Chavez, Ariel Grajales, Jose Sandoval-Sus, et al.
American Journal of Hematology|August 16, 2023
The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCLKai Rejeski, Yucai Wang, Omar Albanyan, et al.
Journal of Hematology & Oncology|July 31, 2023
The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myelomaKai Rejeski, Doris K Hansen, Radhika Bansal, et al.
Haematologica|June 13, 2012
A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantationJoseph Pidala, Jongphil Kim, Heather Jim, et al.
Journal for Immunotherapy of Cancer|May 17, 2022
The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCLKai Rejeski, Ariel Perez, Gloria Iacoboni, et al.
Transplantation and Cellular Therapy|January 29, 2023
Paving the Road for Chimeric Antigen Receptor T Cells: American Society for Transplantation and Cellular Therapy 80/20 Task Force Consensus on Challenges and Solutions to Improving Efficiency of Clinical Center Certification and Maintenance of Operations for Commercially Approved Immune Effector Cell TherapiesSarah Nikiforow, Matthew J Frigault, Noelle V Frey, et al.
Transplantation and Cellular Therapy|March 30, 2021
Incidence and Management of Effusions Before and After CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Large B Cell LymphomaAbu-Sayeef Mirza, Ambuj Kumar, Hamza Hashmi, et al.
Transplantation and Cellular Therapy|August 26, 2024
Tocilizumab Prophylaxis Following Axicabtagene Ciloleucel in Relapsed or Refractory Large B-Cell LymphomaFrederick L Locke, Sattva S Neelapu, Nancy L Bartlett, et al.
Journal for Immunotherapy of Cancer|February 9, 2025
Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registryDaniel J Landsburg, Matthew J Frigault, Michael Heim, et al.
Pageof 24